On September 18, 2024, Flora Growth Corp. (NASDAQ: FLGC) (FSE: 7301) announced a strategic supply agreement with Blossom Genetics to introduce two exotic cannabis strains, Chemmy Jones and Northern Lights, to the German market. This partnership aims to meet the increasing demand for high-quality medical cannabis in Germany following the legalization of cannabis on April 1, 2024.
Flora’s subsidiaries have been active in the German market since 2017, holding the first medical cannabis license in the country and operating an EU-GMP facility. With a distribution network reaching over 1,200 pharmacies in Germany, Flora is well-positioned to deliver these sought-after cannabis strains to the market.
The agreement with Blossom Genetics allows Flora to leverage its distribution expertise and provide Chemmy Jones and Northern Light to meet the evolving demands of the German medical cannabis market. This partnership aligns with Flora’s strategy to scale its operations in Europe and ensure patients in Germany have access to high-quality cannabis products.
Clifford Starke, Chairman, and CEO of Flora Growth Corp., emphasized the significance of this supply agreement in expanding the company’s global presence and meeting the growing demand for medical cannabis in Germany post-legalization.
This press release contains forward-looking statements, reflecting Flora’s expectations and projections about future events. These statements are subject to various risks and uncertainties, as detailed in Flora’s filings with the Securities and Exchange Commission. Flora disclaims any obligation to update or revise forward-looking statements based on new information or events.
For more information, visit Flora Growth Corp.’s website. Source: Flora Growth Corp.
